Skip to main content
Signal8

Profound Medical Corp. (PROF)

Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Profound Medical Corp. logo

Profound Medical Corp.

NASDAQ:PROFHealthcare
+12.12%$6.57
AH$6.57+0.00%vs close
Mkt Cap$240.02M
Float35.63M
O/S36.53M
Vol
$ Vol
RVOL
Inst Own44.1%
SI4.4%
Earnings
Dilution
Pipeline4 lead-sponsored trials·3 active1 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Not applicable
    Completed

    Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

    MR-Guided Transurethral US Ablation of Prostate Tissue

    Prostate Cancer

    Enrollment
    30
    Start
    Mar 2013
    Primary Completion
    Mar 2015
    Completion
    Jun 2019
    NCT01686958
  • Not applicable
    Active, not recruiting

    Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

    MRI-guided Transurethral Ultrasound Ablation

    Prostate Cancer

    Enrollment
    150
    Start
    Sep 2016
    Primary Completion
    Feb 2019
    Completion
    Sep 2028est.
    NCT02766543
  • Observational
    Recruiting

    Customized TULSA-PRO Ablation Registry

    TULSA Procedure

    Prostate Cancer, Prostate Adenocarcinoma +1

    Enrollment
    1,000
    Start
    Oct 2021
    Primary Completion
    Oct 2026est.
    Completion
    Oct 2061est.
    NCT05001477
  • Not applicable
    Active, not recruiting

    A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer

    Radical Prostatectomy, TULSA Procedure

    Prostate Cancer, Prostate Adenocarcinoma

    Enrollment
    201
    Start
    Nov 2021
    Primary Completion
    Aug 2026est.
    Completion
    Aug 2036est.
    NCT05027477